Chris Richard

Chris Richard is Portfolio Manager of Healthcare at Monashee Investment Management, LLC.  Prior to Monashee, Mr. Richard was Head of Public Research at Samsara BioCapital, a biotech/diagnostics-focused private equity firm where he focused on public equities and some select private investments. Previously, Mr. Richard was an SVP, Research at Tekla Capital Management, a closed end healthcare specific mutual fund spun off from JP Morgan’s H&Q Asset Management group. Prior to Tekla, he spent 12 years with Merlin BioMed as a Partner/Head of Research in their mezzanine finance group focusing on late-stage private investments, PIPEs and various long-short public equities strategies. Before joining the investment field, Mr. Richard was an Associate Scientist in the Allergy and Inflammation Group at the Schering-Plough Research Institute where he focused on all stages of drug discovery and early clinical development. He is on the Board of Leap Therapeutics (LPTX) and is on the Advisory Board of the Ty Louis Campbell Foundation, a pediatric brain tumor-focused foundation based in New York.

Mr. Richard received a B.S. in Cell and Molecular Biology from Purchase College, SUNY, an M.S. in Biochemistry from NYU, GSAS and an MBA from NYU, Stern School of Business with a concentration in Finance.